O23 Impact of body mass index on outcomes in thromboembolic disease

Laboratory monitoring of low-molecular-weight heparin therapy—part II

“…Thus, any differences should be attributed to the higher frequency of renal insufficiency in the elderly. Finally, we failed to find any increase in either bleeding complications or recurrent VTE in pregnant patients with VTE [6]. Thus, according to our findings, laboratory monitoring of LMWH should be restricted to patients with either very low body weight or renal insufficiency.…”

“…In several of the early clinical trials of LMWH, both for prophylaxis and treatment, monitoring was carried out in order to gain information and correlations were established between concentration of LMWH, as measured by antifactor-Xa (anti-Xa) assays, and clinical outcome in terms of thrombosis and hemorrhage (see, for example, [3][4][5][6][7]). However, despite these general correlations, there was no relationship at the individual patient level between anti-Xa level and propensity to bleeding, therefore monitoring will not necessarily be helpful to clinical decision-making on an individual patient.…”